Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 10/20 | 0.49 |
| ▸ | MMP9 | P14780 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302189 | 0.83 | SMN1; SMN2 (0.46) | MAPTMMP2MMP9LMNASMN1; SMN2 | |
| SCHEMBL24279553 | 0.81 | SMN1; SMN2 (0.58) | MAPTKDM4EMMP2MMP9LMNA | |
| SCHEMBL14805378 | 0.81 | SMN1; SMN2 (0.43) | MAPTKDM4EMMP2MMP9LMNA | |
| SCHEMBL24279544 | 0.80 | MMP2 (0.50) | MAPTKDM4EMMP2MMP9LMNA | |
| SCHEMBL24279576 | 0.78 | MMP2 (0.60) | MAPTMMP2MMP9LMNA | |
| SCHEMBL24279578 | 0.78 | LMNA (0.54) | MAPTKDM4EMMP2MMP9LMNA | |
| SCHEMBL24279577 | 0.77 | LMNA (0.53) | MAPTKDM4EMMP2MMP9LMNA | |
| SCHEMBL4935409 | 0.75 | ALDH1A1 (0.48) | MMP2MMP9LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4050666 | 0.71 | MLYCD (0.41) | MAPTLMNA | |
| SCHEMBL3379013 | 0.70 | ALDH1A1 (0.56) | MAPTKDM4ELMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025845-A1 | METASTASIS-INHIBITING COMPOSITION OF NOVEL METHYLSULFONAMIDE DERIVATIVE COMPOUND | BIOMEDIGEN INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025845-A1 | METASTASIS-INHIBITING COMPOSITION OF NOVEL METHYLSULFONAMIDE DERIVATIVE COMPOUND | BIOMEDIGEN INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2022050803-A1 | METASTASIS-INHIBITING COMPOSITION OF NOVEL METHYLSULFONAMIDE DERIVATIVE COMPOUND | 한국생명공학연구원 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025845-A1 | METASTASIS-INHIBITING COMPOSITION OF NOVEL METHYLSULFONAMIDE DERIVATIVE COMPOUND | CSE1L, RCC1, PSPC1 | MAPT 1321/4885KDM4E 691/4885MMP2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.